Provided by Tiger Trade Technology Pte. Ltd.

TransCode Therapeutics Inc.

1.69
0.0000
Post-market: 1.690.00000.00%19:30 EDT
Volume:11.45K
Turnover:19.41K
Market Cap:28.61M
PE:-0.03
High:1.74
Open:1.68
Low:1.63
Close:1.69
52wk High:20.99
52wk Low:1.63
Shares:16.93M
Float Shares:2.15M
Volume Ratio:0.33
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-50.6904
EPS(LYR):-52.5900
ROE:-59.28%
ROA:-19.90%
PB:-1.03
PE(LYR):-0.03

Loading ...

TransCode Therapeutics Announces CFO Resignation and Interim Appointment

TIPRANKS
·
Yesterday

TransCode Therapeutics Appoints John Tattory as Interim CFO

Reuters
·
Sep 11

TransCode Therapeutics CFO Tom Fitzgerald Retires; John Tattory Named Interim CFO

Reuters
·
Sep 11

Transcode Therapeutics - Appoints John Tattory as Interim Chief Financial Officer Effective Immediately

THOMSON REUTERS
·
Sep 11

Transcode Therapeutics Announces Leadership Transition

THOMSON REUTERS
·
Sep 11

Press Release: TransCode Therapeutics Announces Leadership Transition

Dow Jones
·
Sep 11

TransCode Says Preclinical Study Shows Survival Benefit for TTX-MC138 in Breast Cancer Bone Metastasis Model

Reuters
·
Aug 31

Tempest Therapeutics Names Nicholas Rossettos CFO, Replacing Justin Trojanowski

Reuters
·
Aug 25

Transcode Therapeutics Says DEFJ LLC Files Initial Beneficial Ownership Statement

Reuters
·
Aug 06

TransCode Therapeutics Updates Preferred Stock Governance Terms

TIPRANKS
·
Aug 04

TransCode Therapeutics Shareholders Approve Key Capital Measures

TIPRANKS
·
Jul 21

Transcode Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jul 21

TransCode Therapeutics Updates Preferred Stock Ownership Limits

TIPRANKS
·
Jul 18

Transcode Therapeutics Adjourns Annual Shareholder Meeting to July 20 Pending NASDAQ Review

Reuters
·
Jul 03

TransCode Therapeutics publishes investor presentation on RNA therapeutics, cancer vaccines and oncolytic immunotherapy platforms

Reuters
·
Jun 18

TransCode Highlights Progress of Lead RNA Cancer Therapeutic

TIPRANKS
·
Jun 18

TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a

MT Newswires Live
·
Jun 03

TransCode Therapeutics reports Phase 1a trial of TTX-MC138 meets safety endpoint in metastatic cancer

Reuters
·
Jun 03

Transcode Therapeutics - Ttx-Mc138 Advances to Phase 2a Clinical Development in Ctdna-Positive Colorectal Cancer

THOMSON REUTERS
·
Jun 03

Transcode Therapeutics - Phase 1a Trial Meets Safety Endpoint With No Dose-Limiting Toxicities

THOMSON REUTERS
·
Jun 03